Bryant CLN, Colbert K, Hompesch M, Chaves S, et al. GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial. Diabetes Obes Metab 2025 Aug 6. doi: 10.1111/dom.16664.
PMID: 40767317